SAN FRANCISCO: Bay Area biotech giant Genentech has promoted from within to fill two key vacancies in its corporate communications department.
SAN FRANCISCO: Bay Area biotech giant Genentech has promoted from
within to fill two key vacancies in its corporate communications
The San Francisco-based drug company, currently in the midst of an IPO
(parent company Roche is spinning off 15% of Genentech stock) last week
promoted senior director of corporate communications Laura Leber to VP
of corporate communications, while senior corporate communications
manager Marie Kennedy moved up to associate director for corporate
Leber is responsible for all standard corporate PR, including
communications relating to corporate earnings, advocacy relations,
employee communications and community relations. She reports to EVP/CFO
Louis Lavigny Jr.
Kennedy will oversee all of Genentech’s brand PR for therapeutic
products, effectively replacing Paul Laland, who left in July to head up
a new biotech/medical technology division for GCI/San Francisco (PRWeek,
Kennedy’s previous post, in which she oversaw all corporate
communications and investor relations, is still vacant. The company has
not announced a timetable for replacing her.
Genentech is considered among the leading innovators in the biotech
Among its seven products manufactured and marketed in the US is the
Pulmozyme Inhalation Solution, the first therapeutic approach for
treating cystic fibrosis in 30 years.